Fluorescence contrast and threshold limit: implications for photodynamic diagnosis of basal cell carcinoma.
This study was designed to evaluate what application time of delta-5-aminolaevulinic acid (ALA) results in highest contrast between tumour and normal skin, in the interval 1-4 h, when using photodynamic diagnosis (PDD) of basal cell carcinomas (BCC) located on the face. Moreover, a value of the demarcation limit has been derived based on the fluorescence variation in normal skin adjacent to the tumour. Forty patients were included in the study, randomly allocated to four different groups with varying ALA application time in the range 1-4 h. The contrast, defined as the ratio between the fluorescence intensity in ALA-treated tumour tissue and normal skin, was calculated for each patient, and the mean values in each group were evaluated as a function of ALA application time. In addition, the fluorescence intensity variation in ALA-treated normal skin adjacent to the tumour was assessed. The results from this study show a peak of the mean contrast values after 3 h ALA application, but due to large interpatient variation, the mean contrast did not differ significantly in the interval 2-4 h. After 2 h ALA application, the fluorescence intensity variation in the normal ALA-treated skin was found to be at a maximum, which suggests that 2 h ALA application is not preferable when using PDD. Based on data of the fluorescence variation in ALA-treated normal skin after 3 and 4 h ALA application, a tolerance interval was calculated implying that values above 1.4 times the mean normal fluorescence indicate an abnormal condition. This tolerance limit agrees well with results obtained in a former study.
Ericson
Marica B
MB
Department of Experimental Physics, School of Physics and Engineering Physics, Chalmers University of Technology-Göteborg University, Göteborg, Sweden. mica@fy.chalmers.se
Sandberg
Carin
C
Gudmundson
Fredrik
F
Rosén
Arne
A
Larkö
Olle
O
Wennberg
Ann-Marie
AM
D000287:Administration, Topical; D000622:Aminolevulinic Acid; D002280:Basal Cell Carcinoma / Q000175:diagnosis* / Q000473:pathology; D005153:Facial Neoplasms / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008856:Microscopy, Fluorescence / Q000379:methods*; D017319:Photosensitizing Agents; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000473:pathology
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid